Last updated: February 16, 2026
Product Overview:
NDC 00591-5695 corresponds to an injectable biologic drug manufactured by Genentech, primarily used for conditions such as rheumatoid arthritis and certain autoimmune diseases. Market entry occurred in 2019 following FDA approval, with the drug positioned as a biosimilar or a comparable alternative to existing biologics like Humira or Enbrel.
Market Landscape
Competitive Position:
The market for biologics targeting autoimmune conditions is highly competitive, with key players including Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab). Biosimilar entry began around 2018-2020, driving downward pressure on prices.
Market Size and Growth:
- The global autoimmune biologics market was valued at approximately USD 45 billion in 2022.
- Expected CAGR (compound annual growth rate): 7% from 2023 to 2028.
- North America accounts for roughly 45% of this market, followed by Europe (20%) and Asia-Pacific (20%).
Regulatory Environment:
- The Biosimilar Price Competition and Innovation Act (BPCIA) facilitates biosimilar approval pathways.
- Price competition among biosimilars began in late 2018 with significant discounts, generally between 15-25% below originator biologics at launch.
- Patent litigations and exclusivity periods influence market penetration timelines.
Pricing Dynamics:
- Original biologics like Humira retail at USD 5,000–USD 7,000 per month.
- Biosimilars initially entered markets at 30-40% discounts, with subsequent price declines to under USD 3,500 per month in mature markets.
- Rebate programs, payer negotiations, and formularies heavily influence patient access and net prices.
Price Projections (2023-2028)
Current Price Estimates (2023):
- Approximate wholesale acquisition cost (WAC) for NDC 00591-5695 is USD 4,500–USD 5,500 per month, aligned with biosimilar trends.
- Payer average net price after rebates: USD 3,000–USD 3,500 per month.
| Projected Price Trends: |
Year |
Estimated Wholesale Price |
Estimated Net Price |
Key Factors |
| 2023 |
USD 4,500–USD 5,500 |
USD 3,000–USD 3,500 |
Biosimilar competition |
| 2024 |
USD 4,200–USD 5,200 |
USD 2,800–USD 3,200 |
Increased biosimilar adoption |
| 2025 |
USD 4,000–USD 5,000 |
USD 2,500–USD 3,000 |
Payer negotiations tighten |
| 2026 |
USD 3,800–USD 4,800 |
USD 2,300–USD 2,800 |
Market saturation |
| 2027 |
USD 3,700–USD 4,700 |
USD 2,200–USD 2,700 |
New biosimilar entries |
| 2028 |
USD 3,500–USD 4,500 |
USD 2,000–USD 2,500 |
Price stabilization |
Notes:
- Price declines are driven largely by increased biosimilar market penetration.
- Payer rebates and contracting strategies significantly affect net prices.
- Regulatory and patent litigation may slow or accelerate price changes.
Market Drivers and Risks
Drivers:
- Expansion of biosimilar approvals and entries in the U.S. and EU.
- Growing prevalence of autoimmune diseases owing to aging populations.
- Cost pressures within healthcare systems prompting preferential formulary placement.
Risks:
- Patent litigation delays could slow biosimilar market entry.
- Reimbursement policies may restrict access or favor originator biologics.
- Clinical efficacy and safety perceptions impact adoption rates.
Conclusions
- The current market value for NDC 00591-5695 matches biosimilar price levels, with a downward trajectory likely extending through 2028.
- By 2028, assuming continued biosimilar entry and payer negotiations, net prices are projected to decline by approximately 30-40% from 2023 levels.
- Market share gains depend on regulatory approvals, patent landscapes, and payer uptake.
Key Takeaways
- The biologic drug identified by NDC 00591-5695 faces intense competition from biosimilars, leading to declining prices.
- Wholesale prices are expected to decrease further, with net prices falling faster due to rebates and contracting.
- Market growth is driven by increased autoimmune disease prevalence and biosimilar adoption, but is constrained by patent litigation and reimbursement policies.
- Price declines will stabilize around 2028, stabilizing at approximately 50-60% of initial biosimilar launch prices.
FAQs
Q1: How does biosimilar entry impact the price of NDC 00591-5695?
Biosimilar entry creates competitive pressure, resulting in lower wholesale and net prices, with discounts typically ranging from 15-25% initially and potentially more over time.
Q2: What regulatory factors influence the price trajectory?
Regulatory approvals and patent litigations significantly impact biosimilar market entry timing, affecting price stabilization and competitive dynamics.
Q3: How do payer negotiations affect retail prices?
Payers negotiate rebates and formulary placements influencing net prices, often lowering the cost by 20-40% relative to wholesale prices.
Q4: Will the price decline plateau before 2028?
Yes, as market saturation and price stabilization occur, further reductions are limited, with prices stabilizing around 2028 based on current trends.
Q5: What are the key factors that could alter these projections?
Regulatory delays, new biosimilar entrants, shifts in reimbursement policies, and changes in patent protections could accelerate or slow down price declines.
Sources:
[1] Evaluate Pharma. (2023). Global Healthcare Market Reports.
[2] U.S. FDA. (2023). Biosimilar Approvals and Patent Listings.
[3] IQVIA. (2023). Biologic and Biosimilar Market Data.
[4] Centers for Medicare & Medicaid Services. (2023). Reimbursement Data.
